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The ultimate aim of any vaccine is to produce
long-term protective immune responses against
a pathogen. These responses include systemic
humoral antibodies that neutralize invasive
organisms and cytotoxic T cells, which are
required to clear certain infections, particularly
chronic viral infections such as HIV (1). Helper
T-cell and cytokine responses also influence
humoral and cellular immune responses (2). For
most bacteria and viruses, the first encounter
with their host involves attachment to a
eukaryotic cell surface, which results in
colonization of the host prior to disease. In such
cases, induced antibody responses at the mucosal
surface could prevent attachment and abrogate
colonization. The ideal target for such antibod-
iessurface proteins known as adhesins
mediate microbial attachment to host tissue (3).
We review recent advances in the identification,
isolation, and purification of adhesins (and
putative adhesins) that could serve as vaccines to
elicit such responses. Studies of at least one
adhesin, the FimH protein from uropathogenic
Escherichia coli, show that antiadhesin
antibodies can block microbial attachment and
subsequent disease. Furthermore, while specific
induction of immune responses along the
mucosal surface by mucosal immunization may
have its advantages (4-7), the FimH studies
demonstrate that immunoglobulin (Ig) G
antibodies alone, which transudate into secre-
tions after parenteral vaccination with the FimH
adhesin, are sufficient to block colonization and
infection.
The Role of Adhesins in Microbial
Pathogenesis
To initiate infection, bacterial pathogens
must first be able to colonize an appropriate
target tissue of the host (8,9). This tropism
(ability to gain access to a niche within the body),
in association with the ability of the bacterium to
breach mucosal barriers and invade the host,
distinguishes pathogenic from commensal or-
ganisms. Colonization begins with the attach-
ment of the bacterium to receptors expressed by
cells forming the lining of the mucosa (Figure 1A,
1B). Certain species of bacteria are restricted in
terms of the hosts and tissues they infect and the
diseases they cause. In many cases, tropism for
specific tissues has been corroborated in the
laboratory by in vitro binding assays with
isolated epithelial cells collected from sites of
infection or from infection-prone hosts.
Attachment is mediated by adhesin proteins;
bacterial lectins are the most common type of
adhesin among both gram-negative and gram-
positive bacteria (3,10-12). Adhesins, such as the
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Blocking the primary stages of infection, namely bacterial attachment to host cell
receptors and colonization of the mucosal surface, may be the most effective strategy
to prevent bacterial infections. Bacterial attachment usually involves an interaction
between a bacterial surface protein called an adhesin and the host cell receptor. Recent
preclinical vaccine studies with the FimH adhesin (derived from uropathogenic
Escherichia coli) have confirmed that antibodies elicited against an adhesin can impede
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Figure 1. Four mechanisms of bacterial adherence where anti-adhesin vaccines could potentially block
colonization and infection. A shows pili or fibrillae protruding from the bacterial surface. These proteinaceous
appendages bind to host cell surface molecules, usually carbohydrates, by adhesin proteins located at the distal
tip of the pilus/fibrillar organelle. Antibodies targeting the adhesin protein block the bacterial/host interaction.
B demonstrates a similar process of bacterial/epithelial cell interactions mediated by afimbrial adhesin
proteins. In this case, antibodies directed against the bacterial surface proteins should also block attachment
and colonization by impeding the ability of the bacteria to associate with mucosal tissues. C illustrates that
some bacteria establish intimate associations with eukaryotic cells by intimin proteins, resulting in
cytoskeletal rearrangements, host cell signaling, possible internalization of the bacteria, and in many cases
systemic disease. Blocking the intimate association/adherence may also be another strategy to prevent
bacterial infections. D shows a novel mechanism whereby bacteria secrete their own receptor protein, which is
internalized by the target host cell, phosphorylated, and embedded in the eukaryotic cell as a new receptor for
tight binding by the bacterium. Theoretically, blocking the secreted receptor (Hp90) before it is internalized by
the host cell could provide another mechanism to block bacterial adherence and infection.
FimH adhesin produced by most Enterobacteri-
aceae (including uropathogenic E. coli), are
highly conserved proteins (13). This lack of major
variation is most likely due to the requirement
that all pathogenic strains recognize invariant
host receptors. Although minor changes in the
adhesin protein have been observed (2%
divergence) and correlate with decreased or
increased affinity for binding to sugars (14),
antibodies against a single FimH protein cross-
react with >90% of E. coli strains expressing the
FimH adhesin and block binding to bladder cells
in vitro (15,16). Furthermore, antibodies against
FimH from a single isolate protect against in vivo397 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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Table 1. Adhesins of gram-negative bacteria
Adhesin Strain Ligand Reference
Pili familya Hultgren (33)
  PapG Escherichia coli Gala(1-4)Gal in globoseries of glycolipids
  SfaS E. coli a-sialyl-2,3-b-galactose
  FimH E. coli Mannose-oligosaccharides
  HifE Haemophilus influenzae Sialylyganglioside-GM1
  PrsG E. coli Gala(1-4)Gal in globoseries of glycolipids
  MrkD Klebsiella pneumoniae Type V collagen
FHA Bordetella pertussis Sulfated sugars on cell-surface Brennan (34)
  glycoconjugates
Pertactin B. pertussis Integrins Brennan (34)
HMW1/HMW2 H. influenzae Human epithelial cells St. Geme (35)
Hia H. influenzae Human conjunctival cells Barenkamp (36)
Leb-binding adhesin Helicobacter pylori Fucosylated Leb histo-blood group Ilver (37)
  antigens
aRepresentative examples from the large family of pilus-associated adhesins.
FHA, filamentous hemagglutinin; HMW, high molecular weight; Hia, H. influenzae adhesin
colonization by >90% of uropathogenic strains in
a murine model for cystitis (unpub. obs.). This
high degree of antigenic conservation is another
reason why adhesins may serve as ideal
vaccines.
Aside from mediating colonization of the
host, bacterial attachment often results in the
up-regulation or expression of many other
virulence genes encoding various proteins that
allow for invasion of the host (Figure 1C) (17-23).
The proteins can mediate tighter associations
with epithelial cells, trigger epithelial cellactin
filament rearrangements, and induce changes in
host-cell signaling and function. In some cases,
the bacteria may also secrete a protein that
inserts into mammalian cells and serves as a
receptor for its own intimate adherence with the
host (Figure 1D) (24). Given that cross-talk
between pathogenic bacteria and host cells after
microbial attachment may trigger expression of
virulence factors leading to local inflammation or
invasive disease, vaccines that block bacterial
attachment may have multiple advantages.
Many studies have demonstrated the utility
of vaccines against bacterial surface components
in blocking attachment in vitro as well as in vivo
(25-28). However, as understanding of the
mechanisms of attachment has evolved and
characterization of specific adhesin molecules
has been refined, new opportunities have
emerged for the development of adhesin-based
vaccines.
Bacterial Adhesins: Gram-Negative
Organisms
One of the best understood mechanisms of
bacterial adherence is attachment mediated by
cell surface structures called pili or fimbriae. Pili
are long, flexible structures that extend outward
from the bacterial surface of many species of
bacteria and allow for contact between the
bacteria and the host cell. Originally pili were
thought to be homopolymeric structures com-
posed of approximately 1,000 copies of a single
structural subunit (fimbrin) packed in a helical
array. However, for many pili, such as the highly
characterized Type 1 and Pap pili expressed on
E. coli and other Enterobacteriaceae, they are
heteropolymeric structures with minor tip
fibrillae proteins located at the distal end of the
organelle (11). The specific interaction with
receptor architectures on host cell surfaces is
mediated by one of these tip proteins, called
adhesins. For example, FimH adhesin mediates
attachment to  a-D-mannosides (29,30) by type 1
pili, while PapG mediates binding to a-D-gal(1-
4)ß-D-Gal-containing receptors on host cells by
Pap pili (31,32) (Table 1). The specificity of
interaction may be involved in conferring
tropism to the bladder and kidney tissues,
respectively (33,38). Pilus-associated adhesins
have been identified in a number of other
bacteria as well (Table 1).
Not all adhesins are associated with pili.
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putative adhesins on its surface: filamentous
hemagglutinin (FHA) and pertactin (34). FHA is
thought to mediate attachment to sulfated
sugars on cell-surface glycoconjugates, although
it may also have other properties. Pertactin is
thought to mediate binding by the Arg-Gly-Asp
triplet binding sequence characteristic of
integrin-binding proteins, although the role of
this binding activity in the pathogenesis of
Bordetella infections is unclear. Both FHA and
pertactin are components in the recently
approved acellular pertussis vaccine.
In Haemophilus influenzae, two families of
nonpilus adhesins have been identified: high-
molecular weight adhesion proteins (HMW1 and
HMW2) and immunogenic high molecular-
weight surface-exposed proteins, the prototypic
member of which has been designated Hia for
H. influenzae adhesin (35). Both families are
expressed by nontypable H. influenzae, which
colonize the respiratory tract and cause such
diseases as otitis media, pneumonia, and
bronchitis. The HMW proteins, which share
homology with the B. pertussis FHA protein,
mediate specific attachment of H. influenzae to
different types of human epithelial cells in vitro
and have been implicated in directing respira-
tory tract tropism for these organisms. The Hia
protein, in contrast, mediates tight association
with human conjunctival cells and is present
only in H. influenzae strains deficient in HMW1/
HMW2 expression (36). Given the dichotomy
among nontypable strains expressing either
HMW or Hia-like adhesins and the serologic
conservation at least among the HMW1 and
HMW2 proteins, a vaccine based on a
combination of such proteins may be protective
against disease caused by most nontypable
H. influenzae.
Another nonpilus adhesin has been identi-
fied and purified from Helicobacter pylori. The
adhesin, called Leb-binding adhesin, mediates
bacterial adherence to fucosylated Lewis b (Leb)
histoblood group antigens, which are expressed
along the mucosal surface of the gastric
epithelium (37). The Leb-binding adhesin may be
involved in conferring tropism for stomach
epithelium and allowing pathogenic bacteria to
establish an ecologic niche within the gas-
trointestinal tract. In association with other
virulence determinants expressed by H. pylori in
the stomach, the colonization process ultimately
results in ulcer formation.
A unique mechanism has been identified by
which certain strains of enteropathogenic E. coli
that cause severe diarrhea target cells for
attachment: Enteropathogenic E. coli express
and insert their own receptor (Hp90) into
mammalian cell surfaces, thereby allowing the
bacteria to attach and establish intimate contact
with the epithelial cells (24) (Figure 1D).
Although a bacterially encoded receptor for a
cognate adhesin protein (intimin), Hp90 is
expressed and secreted by enteropathogenic
E. coli before colonization; therefore, it may also
serve as a target for vaccine development.
Bacterial Adhesins: Gram-Positive
Organisms
Some of the most well-characterized coloni-
zation factors in gram-positive bacteriathe
polypeptides of the antigen I/II familybind to
salivary glycoproteins in a lectinlike interaction
(11) and promote adhesion to the tooth surface
(Table 2). These proteins include the original
AgI/II from Streptococcus mutans, also known as
SpaP, P1, or PAc, and the Streptococcus sobrinus
SpaA and PAg proteins (39). Streptococcus
gordonii expresses two antigen I/II polypeptides,
SspA and SspB, products of tandem chromo-
somal genes (39).
Surface proteins of the antigen I/II family
contain alanine-rich repeats, which adopt an
a-helical coiled-coil structure, proline rich
repeats, and a carboxy-terminal region that
includes the gram-positive cell wall anchor motif
LPXTG (12,49). Binding activity to salivary
glycoprotein has been attributed to both the
highly conserved alanine rich repeats (50,51)
and the proline-rich repeating sequences (52). In
addition to salivary glycoprotein binding
activity, SspA has been implicated in
coaggregation of S. gordonii with Actinomyces
(39). Such bacterial coaggregation may be
involved in dental plaque formation.
Two other S. gordonii proteins, CshA and
CshB, have also been implicated in coaggregation
with Actinomyces. These adhesins may play a
role in adherence of S. gordonii to immobilized
fibronectin in vitro (52) and in colonization in
vivo (40).
Staphylococcus aureus also expresses
fibronectin-binding adhesins. Two genes encod-
ing for fibronectin-binding proteins have been
identified in S. aureusfnbA and fnbB (41).
Fibronectin binding activity is critical in399 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
Synopses
Table 2: Adhesins of gram-positive bacteria
Adhesin Strain Ligand Reference
Antigen I/II Family Demuth (39)
  Ag I/II, SpaP,
  P1, PAc Streptococcus mutans Salivary glycoprotein
  SspA, SspB Streptococcus gordonii Salivary glycoprotein,
  Actinomyces
  SpaA, PAg Streptococcus sobrinus Salivary glycoprotein
CshA , CshB S. gordonii Actinomyces, fibronectin McNab (40)
FnbA, FnbB Staphylococcus aureus Fibronectin Jonsson (41)
SfbI, Protein F Streptococcus pyogenes Fibronectin Talay (42) Hanski (43)
LraI gamily Burnett-Curley et al. (44)
Jenkinson and Lamont (12)
  FimA Streptococcus parasanguis Salivary glycoprotein
  fibrin
  PsaA Streptococcus pneumoniae Unknown
  ScaA S. gordonii Actinomyces
  SsaB Streptococcus sanguis Salivary glycoprotein
  EfaA Enterococcus faecalis Unknown
CbpA/SpsA/PbcA/ S. pneumoniae Cytokine activated Rosenow (45)
  PspC   epithelial and Hammerschmidt et al. (46)
  endothelial cells, IgA Briles et al. (47)
Smith et al. (48)
pathogenesis because it allows the bacteria to
adhere to extracellular matrix components
including fibronectin and collagen (53). This can
result in cutaneous infections and in life-
threatening bacteremia and endocarditis (54).
Binding to fibronectin is also essential for the
attachment of S. pyogenes to respiratory
endothelial cells. S. pyogenes, a group A
streptococcus, has been implicated in various
diseases from skin and throat infections to sepsis
and shock (55). This binding activity is mediated
by several fibronectin binding proteins. Six
different genes encoding proteins with fibronectin
binding activity have been identified (12). The
most well characterized are two closely related
proteins, SfbI (42) and Protein F (43). Both
proteins are directly involved in the fibronectin-
mediated adherence to epithelial cells.
Another group of extensively studied
streptococcal adhesins is the LraI family of
proteins. Included in this group are FimA
from  S. parasanguis, PsaA from S. pneumoniae,
ScaA from S. gordonii, ScbA from S. crista, SsaB
from  S. sanguis, and EfaA from Enterococcus
faecalis (44,56). These membrane-bound lipopro-
teins are part of a larger family of ATP-binding
cassette metal permeases, involved in the
acquisition of manganese (57).
The adhesins FimA and SsaB have high
affinity for salivary glycoprotein on tooth
surfaces and are involved in colonization of the
oral cavity (58). The FimA adhesin for
S. parasanguis has been localized to the tip of
peritrichous surface fimbria on these bacteria
(58). FimA is also a major virulence factor of
S. parasanguis and binds fibrin (44). The ability
to bind fibrin has been implicated in the
pathogenesis of infective endocarditis.
The  S. pneumoniae homologue of FimA,
PsaA, also has a role in pathogenesis (59,60).
While it commonly colonizes the nasopharynx of
healthy persons, S. pneumoniae is a common
pathogen in children and older adults and a
leading cause of otitis media, bacterial pneumo-
nia, sepsis, and meningitis. Like its homologues,
PsaA may function as an adhesin, according to
initial evidence (61). Insertion inactivation of
psaA resulted in pneumococcal mutants that
exhibited reduced adherence to alveolar epithe-
lial cells in vitro (60). However, the PsaA protein
may be a permease involved in the regulation of
adherence rather than functioning as an adhesin
per se (57,61).
Another pneumococcal protein thought to be
an adhesin is CbpA (45) (also known as SpsA [46]
and PspC [47]), one of a family of choline binding400 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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proteins (CBPs) (i.e., surface proteins
noncovalently associated with the phosphocholine
on the lipoteichoic acid). CbpA was initially
isolated from a mixture of pneumococcal proteins
that were able to bind to a choline affinity
column. The CBP mix was purified from a strain
with an inactivated pspA gene (45). The
exogenous CBP mix inhibited adherence of
pneumococci to type II pneumocytes and
endothelial cells in vitro, suggesting that one or
more of these proteins may act as adhesins. CbpA
was the most abundant component in this mix
and was shown to be on the surface of intact
pneumococci in an indirect fluorescent-labeling
assay. The CbpA protein also reacted strongly
with a pool of human convalescent-phase serum.
CbpA is thought to mediate adherence of
S. pneumoniae to sialic acid and lacto-N-
neotetraose ligands present on cytokine-acti-
vated epithelial and endothelial cells in vitro
(45).  cbpA-defective mutants did not colonize the
nasopharynx of infant rats, further supporting
its function as an adhesin and potential
usefulness as an adhesin-based vaccine (45). In
addition, others have shown that this choline
binding protein (which they called SpsA) has
IgA-binding properties, though the relevance of
this function to pneumococcal pathogenesis is
unclear (46). Yet another group has demon-
strated complement protein C3-binding activity
for this protein, which they termed PbcA (48).
Whatever its role in pathogenesis, we have
demonstrated that the gene for CbpA (SpsA/
PbcA/PspC) is highly conserved among the most
common pneumococcal isolates, further enhanc-
ing its use as a vaccine candidate (62).
Adhesins as Vaccines: FimH as a
Paradigm for Adhesin-Based Vaccines To
Block Colonization
One of the key aspects of proving the
potential efficacy of an adhesin-based vaccine in
vivo is the development of an animal model of
disease that relies on bacterial colonization of the
mucosal epithelium mediated by the specific
adhesin of interest. Although seemingly straight-
forward, testing for protection in small animal
models of disease is difficult for various reasons:
large doses of in vitro grown bacteria are
required to establish mucosal colonization in
animals, which does not necessarily mimic the
course of infection in humans; specific glycopro-
tein receptors for some adhesins are lacking in
animal mucosal tissues that correspond to the
site of colonization in humans; and some
bacterial adhesins that are usually expressed as
part of a larger structure on the bacterial cell
surface (e.g., tip adhesins associated with whole
pili) are difficult to purify. Despite these
difficulties, adhesin-based vaccines have demon-
strated efficacy in protecting against infection,
thus proving the usefulness of such molecules as
subunit vaccines. Research using the FimH
adhesin from E. coli provides one such example.
Type 1 pili have long been implicated in
bacterial urinary tract infections in humans
(63,64). In a murine cystitis model, colonization
of the bladder by E. coli was shown to depend on
growth conditions that favored expression of
type 1 pili and in particular required FimH
(15,65). Thus, the murine model was a valid
small-animal model to prove whether adhesin-
based vaccines might block colonization.
Although purifying large amounts of pilus-
associated adhesin is difficult (because most
adhesins are proteolytically degraded when
expressed as independent moieties), Hultgren et
al. demonstrated that the FimH adhesin could be
stabilized in an active conformation by the
periplasmic chaperone FimC, making it possible
to purify full-length FimH protein. Vaccination
with the FimCH complex elicited long-lasting
immune responses to FimH. Sera from mice
vaccinated with the FimH vaccine inhibited
uropathogenic strains of E. coli from binding to
human bladder cells in vitro. Vaccination with
the FimH adhesin-vaccine reduced in vivo
colonization of the bladder mucosa by >99% in
the murine cystitis model (15). Furthermore, the
FimH vaccine protected against colonization and
disease by uropathogenic strains of E. coli
capable of expressing multiple adhesins. IgG
specific for FimH was detected in the urine of
protected mice, consistent with our original
hypothesis that antibodies directed against an
adhesin protein might protect along the mucosal
surface. Subsequent studies in a primate model
of cystitis have corroborated these findings
(Langermann et al., unpub. data). Furthermore,
in primate studies we demonstrated a direct
correlation between the presence of inhibitory
antibodies in secretions and protection against
colonization and infection.
While IgG antibodies elicited against
adhesins are protective, induction of immune
responses along the mucosa can be augmented401 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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by a variety of antigen delivery systems that
specifically target mucosa-associated lymphoid
tissue and activate the mucosal immune system
(4-7,66). These delivery systems include whole-
inactivated or live-attenuated bacterial and viral
vectors, biodegradable microspheres, liposomes,
transgenic plants, and antigens conjugated to or
coadministered with the cholera toxin B subunit
or attenuated forms of heat labile toxin from E.
coli. Many of these systems hold promise for
future vaccine strategies, but only a few have
been tested in humans for safety and
adjuvanticity. As these mucosal adjuvants
progress further toward approval for use in
humans, testing should be done with adhesin
antigens to determine if induction of local
immune responses enhances the protective
efficacy of adhesin-based vaccines as compared
with conventional parenteral vaccination. Such
studies are under way with the FimH vaccine.
Given the preclinical data with the FimH
vaccine, similar efforts should be directed at
developing adhesin-based vaccines for a wide
range of pathogens. In this regard, additional
efforts should also be focused on developing
mucosal models of infection. The availability of
such models should allow for appropriate
screening of adhesin-based vaccines to prevent
infections by streptococci, staphylococci, and
other pathogens for which vaccine coverage is
absent or inadequate.
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